Pocket Guide for Antibiotic Pharmacotherapy

"Where bacteria normally live" Microbiome Man

Drug

Beta-hemolytic streptococci Viridans group streptococci

Streptococcus pneumoniae

Staphylococcus aureus (MSSA) Staphylococcus aureus (MRSA) Oxacillin

±

+

+

+

+

+

+


+

+

+

+ +

+




Antibiotic Pharmacokinetics & Pharmacodynamics

±

+

+

Concentration-dependent Iime-dependent **M**etronidazole Chloramphenicol Fluoroquinolones səpimenotlu**2 C**arbapenems **T**etracyclines Clindamycin (lincosamides) Cephalosporins Trimethoprim Erythromycin (macrolides) **V**ancomycin "Very Proficient For Complete Cell Murder" "ECSTaTiC for bacteriostatic" Bacteriostatic versus Bactericidal




- by maximizing Cmax:MIC ratio Less frequent but higher doses increases efficacy
- Ex: aminoglycosides, daptomycin
- More frequent administration or extended-Optimize killing by maximizing time above MIC

+

+

 Ex: beta-lactam antibiotics infusion increases efficacy by extending T>MIC



Antibiotic Pharmacotherapy by Class

Refer to Guidelines for Dosing in Renal Failure for both dosing in normal renal function and renal dose adjustments				
Antibiotic	Adverse Reactions	Drug Interactions	Clinical Pearls	
Penicillins Penicillin G, oxacillin, ampicillin, amoxicillin	GI upset (nausea, diarrhea) Hypersensitivity reactions Leukopenia, thrombocytopenia (rare) Neurologic (altered mental status, seizures) Interstitial nephritis Hepatotoxicity (oxacillin)	None	Generally drugs of choice for bacteria once susceptibility known (e.g. MSSA, penicillin-susceptible <i>S. pneumoniae</i> , ampicillin-susceptible enterococci)	
Beta-lactam inhibitor combinations amoxicillin-clavulanate, ampicillin-sulbactam, piperacillin-tazobactam		None	Excellent anaerobic activity Sulbactam has unique activity against Acinetobacter spp. (doses based on sulbactam, >6 g/day) Consider amox-clav 500-125 mg q8h dosing for gram-negative, anaerobic, or mixed infections (more clavulanate needed)	
Cephalosporins Cefazolin, ceftriaxone, ceftazidime, cefepime, ceftaroline		None	Cross-reactivity with penicillin allergy <5% Caution with third generation cephalosporins (e.g. ceftriaxone) and SPACE bugs ⁺ (ampC producers)	
Carbapenems Ertapenem, imipenem, meropenem, doripenem		None	Generally reserved for multidrug resistant gram-negatives (MDR-GN) Drug of choice for ESBL producers Excellent anaerobic activity Cross-reactivity with penicillin allergy <5%	
Monobactams Aztreonam		None	Generally reserved for <u>severe</u> penicillin allergy (e.g. anaphylaxis), but may cross-react with ceftazidime allergy	
Fluoroquinolones Ciprofloxacin Moxifloxacin Levofloxacin	GI upset (nausea, vomiting, diarrhea) Neurologic (dizziness, AMS, seizures) Phototoxicity Tendonitis, cartilage erosion QT prolongation Dysglycemia Peripheral neuropathies	Caution with cations (reduced bioavailability) Inhibits 1A2 (cipro)	Increasing resistance may limit use, particularly with E. coli Higher dose for P. aeruginosa (e.g. cipro 750 mg q12h, levo 750 q24h) Highly bioavailable, PO = IV Moxifloxacin = poor urine penetration (not used for UTIs) QT prolongation risk = moxi > levo >> cipro	
Tetracyclines Doxycycline Minocycline Tigecycline	GI upset (nausea, vomiting, epigastric distress) Photosensitivity Teeth discoloration Vertigo (minocycline)	Caution with cations (reduced bioavailability)	Highly bioavailable, PO = IV (doxy, mino) Tige = severe nausea, may need scheduled antiemetics pre-dose Mino, tige = has activity against multidrug resistant organisms (even if tetra or doxy resistant)	

Inhibits 3A (ery > clari >> azi)

None

None

None

None

None

None

Inhibits MAO (weak)

p-glycoprotein substrate

Doxycycline	P
Minocycline	T
Tigecycline	
	·
Macrolides	

Erythromycin, azithromy-

cin, clarithromycin Glycopeptides

Cyclic Lipopeptide

Vancomycin

Daptomycin

Oxazolidinone

Lincosamide

Clindamycin

Sulfonamides

Trimethoprim-

Metronidazole

Nitrofurans

amikacin

Polymyxins

Nitrofurantoin

Aminoglycosides

Colistin, polymyxin B

sulfamethoxazole Nitroimidazole

Linezolid

GI upset (nausea, vomiting, diarrhea) QT prolongation

Neutropenia (rare)

Red man syndrome Nephrotoxicity

Skeletal muscle toxicity Eosinophilic pneumonia

Thrombocytopenia Peripheral neuropathies

GI upset (diarrhea > nausea, vomiting) Elevated LFTs (minor)

Hypersensitivity reactions Leukopenia, anemia Hyperkalemia, renal failure

GI upset (nausea) Peripheral neuropathy Taste disturbances (metallic) Peripheral neuropathy Pulmonary toxicity

Hepatotoxicity (rare)

Nephrotoxicity

Gentamicin, tobramycin, None Ototoxicity Vestibular toxicity Nephrotoxicity None Neurotoxicity (oral/peripheral paresthesias)

May be used synergistically for severe gram-positive infections Ami = may have activity even if gent or tobra resistant Last line for MDR-GNs due to high toxicity risk and limited efficacy Consider polymyxin B for systemic infections and colistin for UTIs

Higher risk for peripheral neuropathies with long-term therapy

Do not use with poor renal function (low urinary penetration)

Low resistance = good option for multidrug resistant organisms

QT prolongation risk = ery >> clari > azi

premedicate with diphenhydramine

Highly bioavailable, PO = IV

Highly bioavailable, PO = IV

Highly bioavailable, PO = IV

Excellent anaerobic activity

Avoid alcohol due to disulfiram reaction

Only used for UTIs, but without pyelonephritis

Tobramycin preferred for P. aeruginosa infections

(e.g. PCP, Nocardia spp.)

MRSA, VRE) if vancomycin failure or resistant

MRSA, VRE) if vancomycin failure or resistant

Higher toxicity risk with long-term therapy (>2 weeks)

Red man syndrome can be prevented by slowing infusion rates or

Generally reserved for severe, resistant gram-positive infections (e.g.

Generally reserved for severe, resistant gram-positive infections (e.g.

Higher risk for serotonin syndrome with due to MAO inhibition with serotonergic agents (e.g. SSRIs, TCAs) and foods (e.g. red wine)

Increasing resistance in S. aureus and streptococci may limit use

Increasing resistance in anaerobes, particularly Bacteroides spp.

Dose for severe infections = 15 mg/kg/day based on TMP component

IV vanc for systemic infections, PO vanc for C. difficile infection

Not for pulmonary infections (deactivated by lung surfactant)

Julius Li, PharmD; Kristi Traugott, PharmD, BCP5 Kevised 3/1 Approfed by P&T Committee 6/2015

+ SPACE bugs = Serratia marcescens, Pseudomonas aeruginosa, Acinetobacter baumannii, Citrobacter freundii, Enterobacter spp.